To investigate whether ARID1A loss and β‐catenin activation synergistically drive liver cancer, we analyzed the co‐occurrence of ARID1A and CTNNB1 mutations in AA‐exposed human HCC samples. This evidence concerns the gene ARID1A and liver cancer.